hotspot -WSS

hotspot

author：comprehensive 2025-08-12 06:44:54 - browse：4

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Morgan Health, with ambitious aims, wants you to know it’s still here

WSS

A single drug, study failures leave Anavex with nothing but cash

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

How to make the FDA’s new prescription one

The biotech scorecard for Q1: 17 stock

Telehealth for opioid use disorder is lifesaving

PEPFAR is under serious threat — and so is global health

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

Long Covid needs a new name — and a new frame

Malaria cases in Florida and Texas: Here’s what you need to know

Feng Zhang, Grail founder join forces on new gene editing startup

DIEP, the 'gold standard' of breast reconstruction, is under threat

Federal weight loss drug coverage is 30 years out of date

Continuity nursing helped my family in our darkest PICU moments

Chronically ill young patients struggle to find fertility info

Wildfire smoke exposes gaps in outdoor worker protections

Burning questions for the 2024 JPM Healthcare Conference

focus

New weight loss drugs vying to be the next Wegovy or Mounjaro

AdventHealth escalates lawsuit against insurance vendor Multiplan

Generate Biomedicines machine learning biotech raises $273M

UCB departs biotech trade group BIO

Goldman Sachs launches $650M fund for life science investments

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Wikipedia

entertainment

focus

focus